FibroScan®
I believe that Fast is a key element for MASH clinical trials by enabling to decrease the screen failure rate and would further be of high interest to identify patients eligible to treatments.
I believe that Fast is a key element for MASH clinical trials by enabling to decrease the screen failure rate and would further be of high interest to identify patients eligible to treatments.